Drugs Made In America Acquisition Corp(DMAA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 58.52 | EPS (ttm) | 0.19 | Insider Own | 23.57% | Shs Outstand | 24.3M | Perf Week | 0.05% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 18.6M | Perf Month | 0.05% |
| Enterprise Value | 0.27B | PEG | - | EPS next Q | - | Inst Own | 49.28% | Short Float | 0.48% | Perf Quarter | 1.63% |
| Income | 0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 3.42 | Perf Half Y | 3.37% |
| Sales | 0.00B | P/B | 1.92 | EPS next 5Y | - | ROA | 3.18% | Short Interest | 0.09M | Perf YTD | 4.92% |
| Book/sh | 5.67 | P/C | 13212.59 | EPS past 3/5Y | - | ROE | 3.33% | 52W High | -0.05% ($10.89) | Perf Year | 5.58% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | 4.42% | 52W Low | 5.68% ($10.30) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 89.22% | Gross Margin | - | Volatility(W/M) | 0.09% 0.12% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.02 | EPS Q/Q | -18.01% | Profit Margin | - | RSI (14) | 65.37 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.02 | Sales Q/Q | - | SMA20 | 0.14% ($10.87) | Beta | 0.01 | Target Price | - |
| Payout | - | Debt/Eq | 0.01 | Earnings | - | SMA50 | 0.65% ($10.82) | Rel Volume | 0.43 | Prev Close | $10.87 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 2.81% ($10.59) | Avg Volume(3M) | 0.03M | Price | $10.89 |
| IPO | 2025/2/25 | Option/Short | No/Yes | Trades | 9 | Volume | 11,253 | Change | 0.14% |
💊 Drugs Made in America Acquisition (DMAA) is a blank check company (SPAC) that does not engage in direct operations. It is a special purpose acquisition company established for the purpose of raising funds through an IPO, placing them in a trust account, and finding a merger target within a set deadline to take it public through a reverse merger. The trust assets are invested in conservative short-term U.S. government bonds and similar instruments, and are preserved until the merger is completed or the company is liquidated.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
Company yardsticks do not fit here, so profitability, valuation and earnings are left out. The other verdicts still apply.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 49.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SPAX T-REX 2X Long SPCX Daily Target ETF 0.03% 
SPAQ Horizon Kinetics SPAC Active ETF <0.01% It ranks #950 of 1434 in the industry
Based on market cap of $264M.
FOA#944 Finance of America Companies Inc $266M PER - 
RMBI#945 Richmond Mutual Bancorporation Inc $266M PER 13.0 
BCBP#948 BCB Bancorp Inc (NJ) $265M PER - DMAA#950 Drugs Made In America Acquisition Corp $264M PER 58.5 
SVIA#953 Silvia Inc $262M PER - 
FAQ
What kind of company is DMAA?
DMAA belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of DMAA?
The market cap of DMAA is approximately $264M, ranking 3,791 within its sector.
What is the P/E ratio of DMAA?
DMAA has a P/E ratio of approximately 58.5x, which can be used to assess its valuation relative to the Financial sector average.
What is the 52-week high and low for DMAA?
DMAA has recorded a 52-week high of $10.89 and a low of $10.30.
